Abstract 221P
Background
The gold standard treatment for the non-muscle invasive bladder cancer (NMIBC) is Bacillus Calmette-Guerin (BCG). the instillation of BCG induces an inflammatory response followed by cytokines upregulation and downregulation with a clinical outcome. In this we are targeting the IL1-alpha and TNF-alpha genes and study their genetic polymorphism to elucidate their role in BCG response and tumor recurrence in NMIBC patients.
Methods
The blood samples collected from histopathologically confirmed 224 NMIBC patients from August 2020 to December 2022. The 124 patients were grouped as BCG nonresponsive (BCG-NR) and 100 patients were grouped under BCG-responsive (BCG-R). The classification of group based on the BCG response followed by SWOG protocol. Recurrence/progression of tumor after 6 months consider for the BCG-NR followed by cystoscopy. In contrast patients with no sign of recurrence and progression after 12 months of BCG therapy consider as BCG-R. The DNA was isolated for the genotypic analysis of IL1A -889 C/T-(rs1800587) and TNFA-1031 T/C (rs1799964), in both groups using Taq-Man Probe-based real-time polymerase chain reactions.
Results
In this study, IL1A -889 C, and TNFA, 1031's C allele frequency, were significantly higher in BCG-NR (P <.05). The IL-1 alpha-889 C/T (CC/CT+TT) and TNFA -1031 T/C (TT/TC+CC) genotype expression were shown to be significantly associated with BCG-NR and tumour recurrence (CC/CT+TT; P=.025, TT/TC+CC; P =0.045) as compared to BCG-R in NMIBC.
Conclusions
The genetic polymorphism of the cytokines IL1A -889 C/T (rs1800587) and TNFA-1031 (rs1799964) T/C is significantly susceptible to the recurrence of tumor, BCG response and lead the way for early therapeutic response in NMIBC patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
217P - Conditional reprogramming of urine-derived bladder cancer cells: A model for precision medicine
Presenter: Yu Dong
Session: Poster Display
Resources:
Abstract
218P - Clinical effectiveness of tislelizumab combined with gemcitabine/cisplatin (GC) versus GC as adjuvant therapy in high-risk muscle-invasive urothelial carcinoma (MIUC): A real-world study
Presenter: xingliang Tan
Session: Poster Display
Resources:
Abstract
219P - Clinical effectiveness of tislelizumab plus TKI as first-line therapy in patients with metastatic renal cell carcinoma (mRCC): A real-world study
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
220P - Heterogeneity in tertiary lymphoid structures predicts distinct prognosis and immune microenvironment characterizations of clear cell renal cell carcinoma
Presenter: Wenhao Xu
Session: Poster Display
Resources:
Abstract
222P - The association between response to enfortumab vedotin and peripheral neuropathy: A multicenter retrospective study in Japan
Presenter: Nozomi Hayakawa
Session: Poster Display
Resources:
Abstract
223P - Patient and healthcare practitioner preferences for treatments in advanced renal cell carcinoma
Presenter: Niara Oliveira
Session: Poster Display
Resources:
Abstract
224P - WUTSUP-01: Phase II trial of neoadjuvant toripalimab and chemotherapy in locally advanced upper tract urothelial carcinoma
Presenter: Yige Bao
Session: Poster Display
Resources:
Abstract
225P - A novel multianalyte signature for stratifying Indian non-muscle invasive bladder cancer: A single center observational study
Presenter: Hari P S
Session: Poster Display
Resources:
Abstract
226P - Prognosis stratification of immunotherapy by a mutational signature in urothelial carcinoma
Presenter: Xuebing Han
Session: Poster Display
Resources:
Abstract
227P - Proteomic analysis of urothelial lesions reveals novel diagnostic biomarkers to distinguish pathologic pitfalls and protein-protein interactions
Presenter: Changlim Hyun
Session: Poster Display
Resources:
Abstract